The risk factors and treatment of rituximab-induced interstitial pneumonia inpatients with diffuse large B-cell lymphoma receiving R-CDOP regimen

LI Feng, WANG Xuli, ZHAO Qian, YAN Qing, ZHAI Yongping

PDF(4446 KB)
Tumor website：www.tumorsci.org E-mail Alert
PDF(4446 KB)
Tumor ›› 2023, Vol. 43 ›› Issue (05) : 428-435. DOI: 10.3781/j.issn.1000-7431.2023.2211-0782
Original Research

The risk factors and treatment of rituximab-induced interstitial pneumonia inpatients with diffuse large B-cell lymphoma receiving R-CDOP regimen

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2023, 43(05): 428-435 https://doi.org/10.3781/j.issn.1000-7431.2023.2211-0782

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(4446 KB)

Accesses

Citation

Detail
Sections
Recommended
Copyright © Tumor, All Rights Reserved.
E-mail: tumor@tumorsci.org
Powered by Beijing Magtech Co., Ltd.

/

〈 〉